세계의 죽종절제 기기 시장 보고서 : 제품 용도, 최종사용자, 지역별(2024-2032년)

The global atherectomy devices market size reached US$ 978.0 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 1,476.0 Million by 2032, exhibiting a growth rate (CAGR) of 4.5% during 2024-2032. The rise in peripheral artery disease (PAD), significant technological advancements, rising ageing population, advent of minimally invasive surgeries, development of healthcare infrastructure, and reimbursement policies in emerging economies represent some of the key factors driving the growth of the atherectomy market.

Atherectomy Devices Market Analysis:

Major Market Drivers: The atherectomy devices market is affected by the increasing cases of peripheral artery disease (PAD) and other cardiovascular diseases. The rising ageing population that is more susceptible to these ailments, along with the rising instances of diabetes, obesity, and smoking, are creating an indirect demand for these devices. Moreover, technological advancements in atherectomy procedures and the growing popularity of minimally invasive surgeries are providing the market with substantial opportunities.

Key Market Trends: The atherectomy devices market is expanding mostly due to significant trends like the increasing cases of PAD and the requirement for minimally invasive surgeries. Advancements in technology enable the production of more advanced devices, which, in turn, give better accuracy and shorter recovery periods. Directional atherectomy systems are also rising in popularity since they allow the user to target and remove atherosclerotic plaque without damaging the vessel wall. In emerging economies, the growth of healthcare infrastructure and better reimbursement situations are propelling atherectomy device availability and usage worldwide.

Competitive Landscape: Some of the major market players in the Atherectomy Devices industry include Abbott Laboratories, Avinger, B. Braun Melsungen AG, Biomerics, Biotronik, Boston Scientific Corporation, C.R. Bard (Becton, Dickinson and Company), Cardinal Health, Koninklijke Philips N.V., Medtronic, Minnetronix Inc., Straub Medical AG (Becton, Dickinson and Company), Terumo Corporation, among many others.

Challenges and Opportunities: The atherectomy devices market suffers from several challenges, including high device costs and tough regulatory requirements that cause delays in product launches. On the contrary, market opportunities are also influenced by the growing incidence of peripheral artery diseases and aging population, which lead to the need for efficacious treatment alternatives. Developments in technology which improve the performance and safety of device provide growth opportunity. In addition, the growth of healthcare infrastructure in the emerging markets creates new fronts of market expansion, which stimulates the worldwide demand for atherectomy procedures.

Atherectomy Devices Market Trends:

Rising Cases of Peripheral Artery Disease (PAD)

The increasing cases of PAD at a global level due to ageing population and the rise in diabetes and obesity is leading the atherectomy device market growth. Approximately, PAD affects 8 to 12 million people in the United States, especially in those over 50. Out of these, 6.5 million over the age of 40 are diagnosed with PAD. Atherectomy devices provide a minimally invasive approach to remove arterial plaque as it is an important alternative in vascular interventions. The device enhances blood flow and reduces symptoms such as leg pain and fatigue. By directly cutting away or vaporizing the plaque, these devices help restore arterial patency, significantly improving patient outcomes in individuals with severe forms of PAD.

Technological Advancements

Major atherectomy devices innovations include the appearance of directionally controlled devices and high-frequency rotational technologies, which have continued to improve the effectiveness and safety of these devices. For instance, a 2020 study suggests that orbital atherectomy (which sands down plaque) effectively opens up blocked leg arteries 90 percent of the time, while laser atherectomy achieves similarly improved blood flow 76 percent of the time. These improvements in patient outcome and surgeon preference for these devices are propelling the growth of the atherectomy devices. In a multicenter study of 172 patients, Jetstream use had a 99% device success, and six-month and 12-month clinically-driven, target-lesion revascularization rates of 15% and 26%, respectively; with a one-year restenosis rate of 38% based on duplex imaging.

Expansion into Emerging Markets

Prominent key players are focusing on emerging economies where healthcare infrastructure development and growing healthcare spending is focused, thereby creating new opportunities for the key players in the market. For instance, the emerging markets of Brazil, Russia, India, China, and South Africa (BRICS) are increasingly shaping the landscape of the global health sector demand and supply for medical goods and services. Health spending as a percentage of GDP in 2030 is projected as - Brazil, 8.4%; Russia, 5.2%; India, 3.5%; China, 5.9%; South Africa, 10.4%. The penetration into these markets is enabled by realization of more advanced treatment alternatives, thus expanding the global footprint of atherectomy devices.

Atherectomy Devices Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional and country levels for 2024-2032. Our report has categorized the market based on product, application, and end user.

Breakup by Product:

Directional Atherectomy Devices

Orbital Atherectomy Devices

Photo-Ablative Atherectomy Devices

Rotational Atherectomy Devices

Support Devices

Directional Atherectomy Devices accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the product. This includes directional atherectomy devices, orbital atherectomy devices, photo-ablative atherectomy devices, rotational atherectomy devices, and support devices. According to the report, directional atherectomy devices represented the largest segment.

Directional atherectomy devices are created to precisely eliminate atherosclerotic plaque from obstructed arteries. These instruments provide the possibility of accurate control, which reduces vessel wall trauma, an important aspect for patient safety and recovery. Their ability to treat complex lesions in multiple vessel sizes makes them to be favoured by vascular specialists leading to the growth of the product segment. The capability of the devices to collect and remove plaque during the procedure sets these devices apart and is in a number of clinical situations preferable.

Breakup by Application:

Peripheral Vascular

Cardiovascular

Neurovascular

Peripheral Vascular accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the application. This includes peripheral vascular, cardiovascular, and neurovascular. According to the report, peripheral vascular represented the largest segment.

The use of atherectomy devices in the treatment of peripheral vascular diseases is important because of the growing prevalence of PAD. Such devices play a key role in reestablishing the blood flow in leg arteries thus help to relieve the symptoms such as pain and mobility problems. The demand in this segment is determined by minimally invasive character of the procedure which allows short recovery period and lower risks of complications in comparison to conventional surgery making patient outcomes and treatment efficiencies higher.

Breakup by End User:

Hospitals

Ambulatory Surgery Centers

Research Laboratories and Academic Institutes

Hospitals accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals, ambulatory surgery centers, and research laboratories and academic institutes. According to the report, hospitals represented the largest segment.

Hospitals are the main users of atherectomy devices because these procedures are very complex and need advanced infrastructure and highly trained healthcare professionals. The growth of the segment is followed by the growth of the number of vascular surgeries conducted in hospitals, fueled by investments into advanced technologies and in the training programs of health providers. Ability of hospitals to offer all types of care including post-operative requirements also helps in making them the dominant subject in the market.

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America dominates the market

The report has also provided a comprehensive analysis of all the major markets which include North America (United States, Canada); Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others); Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others); Latin America (Brazil, Mexico, Others), and Middle East and Africa. According to the report, North America was the largest market for atherectomy devices.

North America is the largest market for atherectomy because of high prevalence of cardiovascular diseases, developed healthcare system and the key market players in the region. The United States is the biggest market in this region because of the favourable reimbursement scenarios, clinical trials, and solid governmental support for research and development in advanced medical devices. The commitment of the region to application of new healthcare solutions is driving the market growth.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have been provided. Some of the major market players in the atherectomy devices market include Abbott Laboratories, Avinger, B. Braun Melsungen AG, Biomerics, Biotronik, Boston Scientific Corporation, C.R. Bard (Becton, Dickinson and Company), Cardinal Health, Koninklijke Philips N.V., Medtronic, Minnetronix Inc., Straub Medical AG (Becton, Dickinson and Company), and Terumo Corporation.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

There is a dynamic market in atherectomy devices with the use of evolving strategies by major players in pursuit to grow their market share and to satisfy the increasing demand for minimally invasive surgery alternatives. One of these approaches is technical oriented, which is to say that the companies invest significantly in R&D to improve their devices that become therefore more efficient and safer. The second common event is strategic alliances and collaborations that support knowledge sharing and better distribution channels. In addition, mergers and acquisitions are common enabling companies to expand their product portfolios and geographical coverage. Approvals by regulatory bodies play an important role here as the companies are trying to meet tough norms that guarantee the efficiency and safety of their products in many markets.

Atherectomy Devices Market News:

In March 2022, B. Braun acquired Intermedt Medizin & Technik GmbH, a specialist in the preparation of dialysis concentrates.

In November 2023, Cardinal Health announced the U.S. launch of its SmartGown EDGE Breathable Surgical Gown with ASSIST Instrument Pockets, created to provide surgical teams safe and convenient instrument access in the operating room.

Key Questions Answered in This Report

• 1. What was the size of the global atherectomy devices market in 2023?
• 2. What is the expected growth rate of the global atherectomy devices market during 2024-2032?
• 3. What has been the impact of COVID-19 on the global atherectomy devices market?
• 4. What are the key factors driving the global atherectomy devices market?
• 5. What is the breakup of the global atherectomy devices market based on the product?
• 6. What is the breakup of the global atherectomy devices market based on the application?
• 7. What is the breakup of the global atherectomy devices market based on the end user?
• 8. What are the key regions in the global atherectomy devices market?
• 9. Who are the key players/companies in the global atherectomy devices market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Atherectomy Devices Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Directional Atherectomy Devices
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Orbital Atherectomy Devices
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Photo-Ablative Atherectomy Devices
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Rotational Atherectomy Devices
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Support Devices
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast

7 Market Breakup by Application

• 7.1 Peripheral Vascular
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Cardiovascular
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Neurovascular
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by End User

• 8.1 Hospitals
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Ambulatory Surgery Centers
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Research Laboratories and Academic Institutes
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Abbott Laboratories
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 Avinger
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
  • 14.3.3 B. Braun Melsungen AG
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
    • 14.3.3.4 SWOT Analysis
  • 14.3.4 Biomerics
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
  • 14.3.5 Biotronik
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 Boston Scientific Corporation
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
    • 14.3.6.4 SWOT Analysis
  • 14.3.7 C.R. Bard (Becton, Dickinson and Company)
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
  • 14.3.8 Cardinal Health Inc.
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
    • 14.3.8.4 SWOT Analysis
  • 14.3.9 Koninklijke Philips N.V.
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
    • 14.3.9.4 SWOT Analysis
  • 14.3.10 Medtronic
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
  • 14.3.11 Minnetronix Inc.
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio
  • 14.3.12 Straub Medical AG (Becton, Dickinson and Company)
    • 14.3.12.1 Company Overview
    • 14.3.12.2 Product Portfolio
  • 14.3.13 Terumo Corporation
    • 14.3.13.1 Company Overview
    • 14.3.13.2 Product Portfolio
    • 14.3.13.3 Financials
    • 14.3.13.4 SWOT Analysis